Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
4.690
+0.150 (3.30%)
Aug 6, 2026, 9:48 AM EDT - Market open
Prelude Therapeutics Market Cap
Prelude Therapeutics has a market cap or net worth of $465.14 million as of August 6, 2026. Its market cap has increased by 627.55% in one year.
Market Cap
465.14M
Enterprise Value
386.43M
1-Year Change
627.55%
Ranking
Category
Stock Price
$4.69
ChartMarket Cap Chart
Since the IPO on September 25, 2020, Prelude Therapeutics's market cap has decreased from $806.64M to $465.14M, a decrease of -42.34%. That is a compound annual growth rate of -8.96%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 6, 2026 | 465.14M | 94.66% |
| Dec 31, 2025 | 238.95M | 147.03% |
| Dec 31, 2024 | 96.73M | -70.04% |
| Dec 29, 2023 | 322.85M | 12.32% |
| Dec 30, 2022 | 287.43M | -50.22% |
| Dec 31, 2021 | 577.35M | -80.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Sep 25, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Q32 Bio | 451.37M |
| Sagimet Biosciences | 441.53M |
| Cabaletta Bio | 438.62M |
| Prothena Corporation | 436.10M |
| Ovid Therapeutics | 434.87M |
| Inhibikase Therapeutics | 431.88M |
| Ocugen | 423.15M |
| Eupraxia Pharmaceuticals | 418.17M |